Refanezumab

立即咨询

Refanezumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1233953-61-1

瑞法奈珠单抗
GSK249320

Refanezumab (GSK249320) 是一种针对髓鞘相关糖蛋白 (MAG) 的 IgG1 型人源化单克隆抗体。Refanezumab 与 MAG 结合并阻断 MAG 介导的轴突再生抑制。Refanezumab 可以在动物中风模型中穿过血脑屏障 (BBB)。Refanezumab 具有用于增强中风后功能恢复研究的潜力。

生物活性

Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed againstmyelin-associatedglycoprotein(MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke^[1]^[2].

体内研究
(In Vivo)

Refanezumab (GSK249320; 10 mg/kg; 静脉给药; 在中风后 24 小时开始并每周继续给药 6 次) 显示神经评分和阶梯测试有更大的增加。Refanezumab 通过静脉注射后，可穿透病变部位，并且在中风后 24 小时对功能结果有轻微影响。

Animal Model:	Male Sprague Dawley rats (weight 361g)^[1]
Dosage:	10 mg/kg
Administration:	IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
Result:	Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.

CAS 号

1233953-61-1

中文名称

瑞法奈珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.